POPHPrograma Operacional do Potencial Humano (Portuguese: Operational Human Potential Program; Lisbon, Portugal; research organization)
POPHPalms of Pasadena Hospital (St. Petersburg, FL)
POPHPre-Optic Periventricular Hypothalamus
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Diagnosis of PoPH. Portal hypertension was diagnosed by clinical symptoms (ascites, history of gastrointestinal hemorrhage, abdominal wall varicose veins, and splenomegaly) and expanded portal vein detected by image examination (abdominal ultrasound or CT).
A number of variables that were significantly different (p < 0.2) between patients with PoPH and patients without PoPH were included in the logistic regression test.
However, little is known about the effectiveness of PAH specific therapy in patients with PoPH since such patients are usually excluded from randomized clinical trials (RCTs) of such therapy because of overall poor survival as well as concerns about adverse drug effects.
The effect of PAH specific therapy on pulmonary hemodynamics is particularly important since PoPH may preclude a patient from undergoing liver transplantation (LT).
Anwar Moin of OPL and representatives of ENI, POPH, OMV, GHPL and the Director General Petroleum Concession were present during the meeting.
Idiopathic pulmonary arterial hypertension (PAH) is included in Group 1 of PAH classification, while pulmonary veno- occlusive disease (PVOD), pulmonary capillary hemangiomatosis (PCH), portopulmonary hypertension (PoPH) and HIV-associated PAH constitute the subgroups of Group I PAH disorders.
Another frequently encountered respiratory problem found in patients with CLD complaining of respiratory problems is portopulmonary hypertension (POPH) (5).
Presented as a late-breaking oral presentation at the European Respiratory Society meeting in France, the PORtopulmonary hypertension Treatment wIth maCitentan - a randOmized clinical trial (PORTICO) showed the safety of macitentan in PoPH was consistent with that observed in previous clinical trials.
Oliveira was financed by "Fundacao para a Ciencia e a Tecnologia" through FSE and POPH Funds (Programa Ciencia 2008).
This work was supported by a grant from the Portuguese Foundation Science and Technology (FCT) (SFRH/BD/72361/2010) / POPH / QRE European Social Fund awarded to the first author.